Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atazanavir/ritonavir versus lopinavir/ritonavir for hospitalized adults with COVID-19
IRCT20200504047298N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Jun 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of atazanavir, ritonavir and lopinavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Clinical and paraclinical findings, Mortality and morbidity rate and 4 more. Started Jun 2020; status: completed.
02
Drugs
atazanavirritonavirlopinavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200504047298N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200504047298N1.